Page last updated: 2024-08-23

pirfenidone and sirolimus

pirfenidone has been researched along with sirolimus in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's5 (71.43)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Latham, CW; Margolin, SB; Visner, GA; Zander, DS; Zhou, H1
Bizargity, P; Hancock, WW; Liu, F; Liu, H; Liu, K; Visner, GA; Wang, L; Yang, J1
Darwiche, K; Freitag, L; Mairinger, FD; Walter, RF; Werner, R; Zarogoulidis, K; Zarogoulidis, P1
Belloli, EA; Flaherty, KR; Martinez, FJ1
Dorca, J; Escobar, I; Llatjós, R; Luburich-Hernaiz, P; Machahua-Huamani, C; Molina-Molina, M; Montes-Worboys, A; Sala-Llinas, E; Vicens-Zygmunt, V1
Hu, H; Li, F; Liu, F; Ma, W; Pan, Q; Ran, C; Wang, J; Yang, Q1

Reviews

1 review(s) available for pirfenidone and sirolimus

ArticleYear
Update in Interstitial Lung Disease 2014.
    American journal of respiratory and critical care medicine, 2015, Sep-01, Volume: 192, Issue:5

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Doxycycline; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Lymphangioleiomyomatosis; Pyridones; Sarcoidosis, Pulmonary; Sirolimus; Smoking; Tomography, X-Ray Computed; Tumor Necrosis Factor-alpha

2015

Other Studies

6 other study(ies) available for pirfenidone and sirolimus

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2005, Volume: 24, Issue:10

    Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cyclosporine; Disease Models, Animal; Female; Graft Rejection; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyridones; Sirolimus; Trachea; Transforming Growth Factor beta

2005
Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses.
    Transplantation, 2009, Aug-15, Volume: 88, Issue:3

    Topics: Adoptive Transfer; Animals; CD8-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Chemokines; Cytokines; Drug Therapy, Combination; Graft Rejection; Heart Transplantation; Histocompatibility; Immunosuppressive Agents; Isoantigens; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyridones; Sirolimus; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Time Factors

2009
Cell viability of fibroblasts to pifenidone and sirolimus: a future concept for drug eluting stents.
    International journal of pharmaceutics, 2014, May-15, Volume: 466, Issue:1-2

    Topics: Apoptosis; Caspase 3; Caspase 7; Cell Line; Cell Survival; Drug-Eluting Stents; Fibroblasts; Humans; Immunosuppressive Agents; L-Lactate Dehydrogenase; Pyridones; Sirolimus

2014
Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells.
    BMC pulmonary medicine, 2018, Apr-27, Volume: 18, Issue:1

    Topics: A549 Cells; Alveolar Epithelial Cells; Biomarkers; Cell Movement; Epithelial-Mesenchymal Transition; Extracellular Matrix; Humans; Idiopathic Pulmonary Fibrosis; Myofibroblasts; Pyridones; Sirolimus; Transforming Growth Factor beta1

2018
A Novel Rabbit Model for Benign Biliary Stricture Formation and the Effects of Medication Infusions on Stricture Formation.
    Digestive diseases and sciences, 2018, Volume: 63, Issue:10

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Agents; Biliary Tract Diseases; Constriction, Pathologic; Disease Models, Animal; Drug Evaluation, Preclinical; Pyridones; Rabbits; Secondary Prevention; Sirolimus; Vasodilator Agents

2018